Chester County News and Community Website
PHILADELPHIA, PA — Geneos Therapeutics announced that two patients with aggressive cancers have achieved long-term survival on its personalized immunotherapy for cancer (PIC) monotherapy, with one patient living more than …
Geneos Reports Long-Term Cancer Survivors on Personalized Immunotherapy Read More
WILMINGTON, DE — AstraZeneca announced positive interim results from its Phase III TULIP-SC trial showing that subcutaneous administration of SAPHNELO (anifrolumab) significantly reduced disease activity in patients with systemic lupus …
AstraZeneca Reports Positive Phase III Data for Subcutaneous Lupus Therapy Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) released new 24-week interim data from its pivotal Phase 3 STOP-HS trials, showing that its oral JAK1 inhibitor povorcitinib (INCB54707) delivered sustained efficacy and …
Incyte Reports Positive 24-Week Data for Povorcitinib in Hidradenitis Suppurativa Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 data showing its investigational oral therapy icotrokinra achieved superior skin clearance compared to deucravacitinib in patients with …
Johnson & Johnson’s Oral Psoriasis Drug Shows Superiority in Phase 3 Trials Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug …
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder Read More
WILMINGTON, DE — NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study evaluating NKT5097, an oral small molecule designed to …
NiKang Therapeutics Advances First-in-Class CDK2/4 Dual Degrader in Phase 1 Study Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in the DUBSTENT DIABETES trial, a new clinical study designed to evaluate whether combining two …
Teleflex Launches Clinical Trial Testing Dual-Device Heart Procedure for Diabetic Patients Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new subgroup analyses from its Phase 3 Launch-HTN trial, showing that its investigational therapy lorundrostat significantly lowered blood pressure across multiple …
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) released new data at the HRX Live 2025 Meeting in Atlanta showing that its atrioventricular interval modulation (AVIM) therapy produces …
Orchestra BioMed Reports Long-Term Data Supporting AVIM Therapy for Hypertension Read More